Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL1617 in Relapsed/Refractory B-cell Lymphoma
NCT07775508Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SL1617 in B cell lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence and Severity of Adverse Events at 24 months and Incidence of Dose-Limiting Toxicities. Started Jun 2026; status: recruiting.
02
Drugs
SL1617
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07775508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07775508.